With the deadline for hospitals to recertify their eligibility for 340B drug discounts arriving on Monday, it appears most facilities will remain qualified—at least for now.
Industry observers say the COVID-19 pandemic’s impact on hospitals’ eligibility for 340B could become
…
The only clear path to resolve the impasse over the legality of 340B contract pharmacy arrangements is for Congress to clarify the 340B law, 340B Report Publisher and CEO Ted Slafsky writes in his latest column for Omnicell.
Urging
…
Hospitals participating in the 340B program provided $67.9 billion in total benefits to their communities in 2018, the American Hospital Association (AHA) reported yesterday. Community benefits represented 13.7% of total 340B hospital expenses, the group said.
AHA broke out
Federal health officials have added New Jersey and New York to the list of states granted 340B enrollment flexibility due to Hurricane Ida.
The U.S. Health Resources and Services Administration (HRSA) posted the notice about the East Coast states’ addition
…
340B covered entities are ramping up their lobbying on Capitol Hill as Congress works toward possible enactment soon of major drug pricing reforms.
Entities are telling key members of Congress and their staffs that while they support federal action to
…
Federal health officials “violated unambiguous statutory commands” in 2018 when they lowered lower Medicare Part B drug reimbursement rates for 340B hospitals by nearly 30% and their decision should be set aside, hospital groups and individual hospitals told the U.S.
…
The Arkansas Insurance Department is holding a public hearing this Friday morning on whether it should strike down as unconstitutional the nation’s first state law to address pharmaceutical manufacturer denials of 340B pricing on drugs when they are dispensed by
…SPONSORED CONTENT
Since its introduction in 1992, the 340B Program has vastly altered the pharmacy landscape. In these very uncertain times, as we continue to grasp COVID-19’s longevity and struggle to predict a tumultuous 340B environment, we see considerable talk about 340B optimization. From expanding contract pharmacy networks
…
Community health centers on Tuesday split their 340B dispute resolution petition against drug manufacturers Eli Lilly, Sanofi, and AstraZeneca into two—one against Lilly alone, the other against Sanofi and AstraZeneca together—to let federal officials commence proceedings against Sanofi and AstraZeneca.
…
Federal health officials are “trying to muscle an obligation” on drug manufacturers to honor 340B contract pharmacy arrangements “that simply is not there,” United Therapeutics (UT) said Tuesday in papers filed in federal district court in Washington, D.C.
Nothing in
…
×
*Sign up for news summaries and alerts from 340B Report
